Details of the Drug

General Information of Drug (ID: DMXKJ6C)

Drug Name
Torasemide
Synonyms
Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1], [2]
Therapeutic Class
Diuretics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 348.4
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2213 mcgh/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 6 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 80% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.53 mL/min/kg [5]
Elimination
Torasemide is mainly hepatically processed and excreted in the feces from which about 70-80% of the administered dose is excreted by this pathway [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [7]
Metabolism
The drug is metabolized via the liver [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.55724 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [5]
Vd
The volume of distribution (Vd) of drug is 0.2 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.16 mg/mL [4]
Chemical Identifiers
Formula
C16H20N4O3S
IUPAC Name
1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
Canonical SMILES
CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
InChI
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
InChIKey
NGBFQHCMQULJNZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
41781
ChEBI ID
CHEBI:9637
CAS Number
56211-40-6
DrugBank ID
DB00214
TTD ID
D0J9XZ
VARIDT ID
DR00222
INTEDE ID
DR1620
ACDINA ID
D00692

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [10], [11], [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8)
Main DME 		DES5XRU CP2C8_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Torasemide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Carvedilol DMHTEAO Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Carvedilol. Heart failure [BD10-BD1Z] [48]
Chlorothiazide DMLHESP Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Chlorothiazide. Heart failure [BD10-BD1Z] [49]
Digoxin DMQCTIH Moderate Increased risk of hypomagnesemia by the combination of Torasemide and Digoxin. Heart failure [BD10-BD1Z] [50]
Hydroflumethiazide DMVPUQI Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Hydroflumethiazide. Heart failure [BD10-BD1Z] [49]
Digitoxin DMWVIGP Moderate Increased risk of hypokalemia by the combination of Torasemide and Digitoxin. Heart failure [BD10-BD1Z] [50]
Coadministration of a Drug Treating the Disease Different from Torasemide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefuroxime DMSIMD8 Moderate Increased renal excretion of Torasemide caused by Cefuroxime. Acute bronchitis [CA42] [51]
Arn-509 DMT81LZ Moderate Accelerated clearance of Torasemide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [52]
Framycetin DMF8DNE Major Increased risk of ototoxicity by the combination of Torasemide and Framycetin. Alcoholic liver disease [DB94] [53]
Oxandrolone DMU9MYJ Moderate Decreased metabolism of Torasemide caused by Oxandrolone mediated inhibition of CYP450 enzyme. Alcoholic liver disease [DB94] [54]
Metronidazole DMTIVEN Moderate Decreased metabolism of Torasemide caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [54]
Cefamandole DMNEXZF Moderate Increased renal excretion of Torasemide caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [51]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Dronedarone. Angina pectoris [BA40] [55]
Promazine DMZAL7W Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Promazine. Appearance/behaviour symptom [MB23] [56]
Voriconazole DMAOL2S Moderate Decreased metabolism of Torasemide caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [54]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Torasemide caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [54]
Cefotetan DM07TX3 Moderate Increased renal excretion of Torasemide caused by Cefotetan. Bacterial infection [1A00-1C4Z] [51]
Kanamycin DM2DMPO Major Increased risk of ototoxicity by the combination of Torasemide and Kanamycin. Bacterial infection [1A00-1C4Z] [53]
Ceftizoxime DM3VOGS Moderate Increased renal excretion of Torasemide caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [51]
Ceftazidime DM41GRA Moderate Increased renal excretion of Torasemide caused by Ceftazidime. Bacterial infection [1A00-1C4Z] [51]
Cefmetazole DM42W1B Moderate Increased renal excretion of Torasemide caused by Cefmetazole. Bacterial infection [1A00-1C4Z] [51]
Loracarbef DM4L8H3 Moderate Increased renal excretion of Torasemide caused by Loracarbef. Bacterial infection [1A00-1C4Z] [51]
Cefoperazone DM53PV8 Moderate Increased renal excretion of Torasemide caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [51]
Amikacin DM5PDRB Major Increased risk of nephrotoxicity by the combination of Torasemide and Amikacin. Bacterial infection [1A00-1C4Z] [53]
Cefprozil DM7DSYP Moderate Increased renal excretion of Torasemide caused by Cefprozil. Bacterial infection [1A00-1C4Z] [51]
Sulfamethoxazole DMB08GE Moderate Decreased metabolism of Torasemide caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Ceftriaxone DMCEW64 Moderate Increased renal excretion of Torasemide caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [51]
Cephalexin DMD5JU8 Moderate Increased renal excretion of Torasemide caused by Cephalexin. Bacterial infection [1A00-1C4Z] [51]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Torasemide and Streptomycin. Bacterial infection [1A00-1C4Z] [53]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Torasemide and Linezolid. Bacterial infection [1A00-1C4Z] [57]
Cefepime DMHVWIK Moderate Increased renal excretion of Torasemide caused by Cefepime. Bacterial infection [1A00-1C4Z] [51]
Cefdinir DMJ7A0H Moderate Increased renal excretion of Torasemide caused by Cefdinir. Bacterial infection [1A00-1C4Z] [51]
Cefpodoxime DMJUNY5 Moderate Increased renal excretion of Torasemide caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [51]
Cefaclor DMJXDGC Moderate Increased renal excretion of Torasemide caused by Cefaclor. Bacterial infection [1A00-1C4Z] [51]
Gentamicin DMKINJO Major Increased risk of nephrotoxicity by the combination of Torasemide and Gentamicin. Bacterial infection [1A00-1C4Z] [53]
Cefadroxil DMMC345 Moderate Increased renal excretion of Torasemide caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [51]
Cefotaxime DMMKHBJ Moderate Increased renal excretion of Torasemide caused by Cefotaxime. Bacterial infection [1A00-1C4Z] [51]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Torasemide and Rabeprazole. Bacterial infection [1A00-1C4Z] [58]
Cefazolin DMPDYFR Moderate Increased renal excretion of Torasemide caused by Cefazolin. Bacterial infection [1A00-1C4Z] [51]
Netilmicin DMRD1QK Major Increased risk of ototoxicity by the combination of Torasemide and Netilmicin. Bacterial infection [1A00-1C4Z] [53]
Cefditoren DMSUVM1 Moderate Increased renal excretion of Torasemide caused by Cefditoren. Bacterial infection [1A00-1C4Z] [51]
Cefonicid DMTX2BH Moderate Increased renal excretion of Torasemide caused by Cefonicid. Bacterial infection [1A00-1C4Z] [51]
Tobramycin DMUI0CH Major Increased risk of nephrotoxicity by the combination of Torasemide and Tobramycin. Bacterial infection [1A00-1C4Z] [53]
Cefradine DMUNSWV Moderate Increased renal excretion of Torasemide caused by Cefradine. Bacterial infection [1A00-1C4Z] [51]
Cefalotin DMVYSLE Moderate Increased renal excretion of Torasemide caused by Cefalotin. Bacterial infection [1A00-1C4Z] [51]
Cefixime DMY60I8 Moderate Increased renal excretion of Torasemide caused by Cefixime. Bacterial infection [1A00-1C4Z] [51]
Cefoxitin DMYTXVR Moderate Increased renal excretion of Torasemide caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [51]
Vismodegib DM5IXKQ Moderate Decreased metabolism of Torasemide caused by Vismodegib mediated inhibition of CYP450 enzyme. Basal cell carcinoma [2C32] [54]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Torasemide and Cariprazine. Bipolar disorder [6A60] [59]
Etidronic acid DM1XHYJ Moderate Increased risk of hypocalcemia by the combination of Torasemide and Etidronic acid. Bone paget disease [FB85] [60]
Risedronate DM5FLTY Moderate Increased risk of hypocalcemia by the combination of Torasemide and Risedronate. Bone paget disease [FB85] [60]
Alendronate DMY2KX9 Moderate Increased risk of hypocalcemia by the combination of Torasemide and Alendronate. Bone paget disease [FB85] [60]
Alpelisib DMEXMYK Moderate Increased metabolism of Torasemide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Toremifene DMQYUWG Moderate Decreased metabolism of Torasemide caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Ceftibuten DMWV2AG Moderate Increased renal excretion of Torasemide caused by Ceftibuten. Bronchitis [CA20] [51]
Sotalol DML60TN Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Sotalol. Cardiac arrhythmia [BC9Z] [48]
Phenylbutazone DMAYL0T Moderate Antagonize the effect of Torasemide when combined with Phenylbutazone. Chronic pain [MG30] [62]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Torasemide when combined with Ketoprofen. Chronic pain [MG30] [62]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Torasemide and Levomilnacipran. Chronic pain [MG30] [63]
Mifepristone DMGZQEF Moderate Decreased metabolism of Torasemide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [64]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Torasemide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [54]
MK-8228 DMOB58Q Moderate Increased metabolism of Torasemide caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [65]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Torasemide and Sertraline. Depression [6A70-6A7Z] [63]
Fluoxetine DM3PD2C Moderate Increased risk of hyponatremia by the combination of Torasemide and Fluoxetine. Depression [6A70-6A7Z] [63]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Torasemide and Vilazodone. Depression [6A70-6A7Z] [63]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Torasemide and Paroxetine. Depression [6A70-6A7Z] [63]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Torasemide and Selegiline. Depression [6A70-6A7Z] [57]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Torasemide and Vortioxetine. Depression [6A70-6A7Z] [63]
Duloxetine DM9BI7M Moderate Increased risk of hyponatremia by the combination of Torasemide and Duloxetine. Depression [6A70-6A7Z] [63]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Torasemide and Isocarboxazid. Depression [6A70-6A7Z] [57]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Torasemide and Milnacipran. Depression [6A70-6A7Z] [63]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Torasemide and Escitalopram. Depression [6A70-6A7Z] [63]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Torasemide and Tranylcypromine. Depression [6A70-6A7Z] [57]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Torasemide and Desvenlafaxine. Depression [6A70-6A7Z] [63]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Torasemide and OPC-34712. Depression [6A70-6A7Z] [59]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Torasemide and Phenelzine. Depression [6A70-6A7Z] [57]
Venlafaxine DMR6QH0 Moderate Increased risk of hyponatremia by the combination of Torasemide and Venlafaxine. Depression [6A70-6A7Z] [63]
Citalopram derivative 1 DMITX1G Moderate Increased risk of hyponatremia by the combination of Torasemide and Citalopram derivative 1. Discovery agent [N.A.] [63]
Valproate DMCFE9I Moderate Decreased metabolism of Torasemide caused by Valproate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Torasemide and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [66]
Timolol DM3NXRU Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Timolol. Essential hypertension [BA00] [48]
Bendroflumethiazide DM7EVLC Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Bendroflumethiazide. Essential hypertension [BA00] [49]
Benzthiazide DMQWZ0H Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Benzthiazide. Essential hypertension [BA00] [67]
Nadolol DMW6GVL Moderate Increased risk of hyperglycemia by the combination of Torasemide and Nadolol. Essential hypertension [BA00] [48]
Mefenamic acid DMK7HFI Moderate Antagonize the effect of Torasemide when combined with Mefenamic acid. Female pelvic pain [GA34] [62]
Miconazole DMPMYE8 Moderate Decreased metabolism of Torasemide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [54]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Torasemide and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [58]
Omeprazole DM471KJ Moderate Increased risk of hypomagnesemia by the combination of Torasemide and Omeprazole. Gastro-oesophageal reflux disease [DA22] [58]
Cisapride DMY7PED Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Cisapride. Gastro-oesophageal reflux disease [DA22] [68]
Carteolol DMFMDOB Moderate Increased risk of hyperglycemia by the combination of Torasemide and Carteolol. Glaucoma [9C61] [48]
Metipranolol DMJMVKI Moderate Increased risk of hyperglycemia by the combination of Torasemide and Metipranolol. Glaucoma [9C61] [48]
Levobetaxolol DMSREPX Moderate Increased risk of hyperglycemia by the combination of Torasemide and Levobetaxolol. Glaucoma [9C61] [48]
Levobunolol DMTNFCQ Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Levobunolol. Glaucoma [9C61] [48]
Sulfinpyrazone DMEV954 Moderate Decreased metabolism of Torasemide caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme. Gout [FA25] [54]
Rifapentine DMCHV4I Moderate Increased metabolism of Torasemide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [69]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Torasemide and Procarbazine. Hodgkin lymphoma [2B30] [57]
Delavirdine DM3NF5G Moderate Decreased metabolism of Torasemide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Torasemide caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Ritonavir DMU764S Minor Increased metabolism of Torasemide caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Torasemide caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [52]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Torasemide caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [54]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Torasemide caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [54]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Torasemide and Etelcalcetide. Hyper-parathyroidism [5A51] [52]
Acebutolol DM0TI4U Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Acebutolol. Hypertension [BA00-BA04] [48]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Torasemide and Moexipril. Hypertension [BA00-BA04] [71]
Bisoprolol DM3UZ95 Moderate Increased risk of hyperglycemia by the combination of Torasemide and Bisoprolol. Hypertension [BA00-BA04] [48]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Torasemide and Captopril. Hypertension [BA00-BA04] [71]
Penbutolol DM4ES8F Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Penbutolol. Hypertension [BA00-BA04] [48]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Torasemide and Trandolapril. Hypertension [BA00-BA04] [71]
Nebivolol DM7F1PA Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Nebivolol. Hypertension [BA00-BA04] [48]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Torasemide and Fosinopril. Hypertension [BA00-BA04] [71]
Pindolol DMD2NV7 Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Pindolol. Hypertension [BA00-BA04] [48]
Indapamide DMGN1PW Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Indapamide. Hypertension [BA00-BA04] [49]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Torasemide and Benazepril. Hypertension [BA00-BA04] [71]
Trichlormethiazide DMHAQCO Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Trichlormethiazide. Hypertension [BA00-BA04] [49]
Labetalol DMK8U72 Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Labetalol. Hypertension [BA00-BA04] [48]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Torasemide and Enalapril. Hypertension [BA00-BA04] [71]
Atenolol DMNKG1Z Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Atenolol. Hypertension [BA00-BA04] [48]
Metoprolol DMOJ0V6 Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Metoprolol. Hypertension [BA00-BA04] [48]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Torasemide and Quinapril. Hypertension [BA00-BA04] [71]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Torasemide and Lisinopril. Hypertension [BA00-BA04] [71]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Hydrochlorothiazide. Hypertension [BA00-BA04] [49]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Torasemide when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [62]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Torasemide and Propiomazine. Insomnia [7A00-7A0Z] [59]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Torasemide and ITI-007. Insomnia [7A00-7A0Z] [59]
Ceritinib DMB920Z Moderate Decreased metabolism of Torasemide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [54]
PF-06463922 DMKM7EW Moderate Increased metabolism of Torasemide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [56]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [72]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Torasemide caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [56]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Torasemide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Torasemide caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [54]
Propranolol DM79NTF Moderate Increased risk of hypertriglyceridemia by the combination of Torasemide and Propranolol. Migraine [8A80] [48]
Pamidronate DMB4AVP Moderate Increased risk of hypocalcemia by the combination of Torasemide and Pamidronate. Mineral excesses [5B91] [60]
Zoledronate DMIXC7G Moderate Increased risk of hypocalcemia by the combination of Torasemide and Zoledronate. Mineral excesses [5B91] [60]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Torasemide and Ozanimod. Multiple sclerosis [8A40] [57]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Torasemide and Methoxsalen. Mycosis fungoides [2B01] [56]
Imatinib DM7RJXL Moderate Decreased metabolism of Torasemide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Droperidol DM0DXA8 Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Droperidol. Nausea/vomiting [MD90] [73]
Prochlorperazine DM53SRA Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Prochlorperazine. Nausea/vomiting [MD90] [56]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Torasemide and Promethazine. Nausea/vomiting [MD90] [59]
Thiethylperazine DMU3IET Moderate Additive hypotensive effects by the combination of Torasemide and Thiethylperazine. Nausea/vomiting [MD90] [59]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Torasemide and Sibutramine. Obesity [5B80-5B81] [63]
Chlorthalidone DM4DMBT Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Chlorthalidone. Oedema [MG29] [49]
Metolazone DMB39LO Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Metolazone. Oedema [MG29] [49]
Polythiazide DMCH80F Moderate Increased risk of fluid/electrolyte loss by the combination of Torasemide and Polythiazide. Oedema [MG29] [49]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Levomethadyl Acetate. Opioid use disorder [6C43] [74]
Rofecoxib DM3P5DA Moderate Antagonize the effect of Torasemide when combined with Rofecoxib. Osteoarthritis [FA00-FA05] [62]
Valdecoxib DMAY7H4 Moderate Antagonize the effect of Torasemide when combined with Valdecoxib. Osteoarthritis [FA00-FA05] [62]
Diclofenac DMPIHLS Moderate Antagonize the effect of Torasemide when combined with Diclofenac. Osteoarthritis [FA00-FA05] [62]
Naproxen DMZ5RGV Moderate Antagonize the effect of Torasemide when combined with Naproxen. Osteoarthritis [FA00-FA05] [62]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Torasemide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [54]
Carboplatin DMG281S Moderate Increased risk of ototoxicity by the combination of Torasemide and Carboplatin. Ovarian cancer [2C73] [75]
Etodolac DM6WJO9 Moderate Antagonize the effect of Torasemide when combined with Etodolac. Pain [MG30-MG3Z] [62]
Diflunisal DM7EN8I Moderate Antagonize the effect of Torasemide when combined with Diflunisal. Pain [MG30-MG3Z] [62]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Torasemide when combined with Ibuprofen. Pain [MG30-MG3Z] [62]
Nabumetone DMAT2XH Moderate Antagonize the effect of Torasemide when combined with Nabumetone. Pain [MG30-MG3Z] [62]
Piroxicam DMTK234 Moderate Antagonize the effect of Torasemide when combined with Piroxicam. Pain [MG30-MG3Z] [62]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Torasemide and Safinamide. Parkinsonism [8A00] [57]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Torasemide and Rasagiline. Parkinsonism [8A00] [57]
Esomeprazole DM7BN0X Moderate Increased risk of hypomagnesemia by the combination of Torasemide and Esomeprazole. Peptic ulcer [DA61] [58]
Ketorolac DMI4EL5 Moderate Antagonize the effect of Torasemide when combined with Ketorolac. Postoperative inflammation [1A00-CA43] [62]
Bromfenac DMKB79O Moderate Antagonize the effect of Torasemide when combined with Bromfenac. Postoperative inflammation [1A00-CA43] [62]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Torasemide caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [54]
Enzalutamide DMGL19D Moderate Increased metabolism of Torasemide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [76]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Torasemide and Verteporfin. Psoriasis [EA90] [52]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Torasemide and Levomepromazine. Psychotic disorder [6A20-6A25] [59]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Torasemide and Fluphenazine. Psychotic disorder [6A20-6A25] [59]
Triflupromazine DMKFQJP Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Triflupromazine. Psychotic disorder [6A20-6A25] [56]
Sulfadiazine DMTW3R8 Moderate Decreased metabolism of Torasemide caused by Sulfadiazine mediated inhibition of CYP450 enzyme. Rheumatic fever [1B40] [54]
Meloxicam DM2AR7L Moderate Antagonize the effect of Torasemide when combined with Meloxicam. Rheumatoid arthritis [FA20] [62]
Sulindac DM2QHZU Moderate Antagonize the effect of Torasemide when combined with Sulindac. Rheumatoid arthritis [FA20] [62]
Celecoxib DM6LOQU Moderate Antagonize the effect of Torasemide when combined with Celecoxib. Rheumatoid arthritis [FA20] [62]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Torasemide when combined with Oxaprozin. Rheumatoid arthritis [FA20] [62]
Flurbiprofen DMGN4BY Moderate Antagonize the effect of Torasemide when combined with Flurbiprofen. Rheumatoid arthritis [FA20] [62]
Fenoprofen DML5VQ0 Moderate Antagonize the effect of Torasemide when combined with Fenoprofen. Rheumatoid arthritis [FA20] [62]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Torasemide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [54]
Indomethacin DMSC4A7 Moderate Antagonize the effect of Torasemide when combined with Indomethacin. Rheumatoid arthritis [FA20] [62]
Tolmetin DMWUIJE Moderate Antagonize the effect of Torasemide when combined with Tolmetin. Rheumatoid arthritis [FA20] [62]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Torasemide and Quetiapine. Schizophrenia [6A20] [59]
Mesoridazine DM2ZGAN Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Mesoridazine. Schizophrenia [6A20] [56]
Thioridazine DM35M8J Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Thioridazine. Schizophrenia [6A20] [56]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Torasemide and Aripiprazole. Schizophrenia [6A20] [59]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Iloperidone. Schizophrenia [6A20] [56]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Paliperidone. Schizophrenia [6A20] [56]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Torasemide and Loxapine. Schizophrenia [6A20] [59]
Haloperidol DM96SE0 Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Haloperidol. Schizophrenia [6A20] [56]
Perphenazine DMA4MRX Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Perphenazine. Schizophrenia [6A20] [56]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Torasemide and Molindone. Schizophrenia [6A20] [59]
Chlorpromazine DMBGZI3 Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Chlorpromazine. Schizophrenia [6A20] [56]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Torasemide and Thiothixene. Schizophrenia [6A20] [59]
Clozapine DMFC71L Moderate Additive hypotensive effects by the combination of Torasemide and Clozapine. Schizophrenia [6A20] [59]
Trifluoperazine DMKBYWI Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Trifluoperazine. Schizophrenia [6A20] [56]
Ziprasidone DMM58JY Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Ziprasidone. Schizophrenia [6A20] [77]
Risperidone DMN6DXL Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Risperidone. Schizophrenia [6A20] [56]
Olanzapine DMPFN6Y Moderate Additive hypotensive effects by the combination of Torasemide and Olanzapine. Schizophrenia [6A20] [59]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Torasemide and Amisulpride. Schizophrenia [6A20] [56]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Torasemide and Asenapine. Schizophrenia [6A20] [59]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Pimozide. Schizophrenia [6A20] [68]
Cephapirin DMV2JNY Moderate Increased renal excretion of Torasemide caused by Cephapirin. Sepsis [1G40-1G41] [51]
LDE225 DMM9F25 Moderate Decreased metabolism of Torasemide caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [54]
Cisplatin DMRHGI9 Moderate Increased risk of ototoxicity by the combination of Torasemide and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [78]
Warfarin DMJYCVW Moderate Decreased metabolism of Torasemide caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [52]
Clopidogrel DMOL54H Minor Decreased metabolism of Torasemide caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [79]
Sulfamethizole DMGCHDS Moderate Decreased metabolism of Torasemide caused by Sulfamethizole mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [54]
Plazomicin DMKMBES Major Increased risk of ototoxicity by the combination of Torasemide and Plazomicin. Urinary tract infection [GC08] [53]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Torasemide and Methdilazine. Vasomotor/allergic rhinitis [CA08] [59]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Torasemide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [59]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Torasemide and Amiodarone. Ventricular tachyarrhythmia [BC71] [80]
⏷ Show the Full List of 202 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Torsemide 100 mg tablet 100 mg Oral Tablet Oral
Torsemide 5 mg tablet 5 mg Oral Tablet Oral
Torsemide 10 mg tablet 10 mg Oral Tablet Oral
Torsemide 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7312).
2 Drug information of Torasemide, 2008. eduDrugs.
3 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Bruggemann RJ: Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Indian Journal of Clinical Practice
7 A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015 Mar;169(3):323-33. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6.
8 Phillipps GH: Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:19-23.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
11 Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. Nephrol Dial Transplant. 2001;16 Suppl 1:14-7.
12 Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43.
13 Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
16 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
17 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
18 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
20 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
21 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
22 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
23 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
24 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
25 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
26 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
27 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
28 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
29 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
30 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
31 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
32 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
33 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
34 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
35 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
36 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
37 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
38 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
39 FDA Drug Development and Drug Interactions
40 Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
41 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
42 Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
43 Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
44 Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
45 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
46 Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
47 The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
48 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
49 Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
50 Semple P, Tilstone WJ, Lawson DH "Furosemide and urinary digoxin clearance." N Engl J Med 293 (1975): 612-3. [PMID: 902451]
51 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Bates DE, Beaumont SJ, Baylis BW "Ototoxicity induced by gentamicin and furosemide." Ann Pharmacother 36 (2002): 446-51. [PMID: 11895059]
54 Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81. [PMID: 7891318]
55 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
56 Cerner Multum, Inc. "Australian Product Information.".
57 Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
58 Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
61 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
62 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
63 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
64 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
65 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
66 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
67 Marone C, Muggli F, Lahn W, Frey FJ "Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man." Eur J Clin Invest 15 (1985): 253-7. [PMID: 3935455]
68 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
69 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
70 Product Information. Kaletra (lopinavir-ritonavir) Abbott Pharmaceutical, Abbott Park, IL.
71 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
72 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
73 Canadian Pharmacists Association.
74 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
75 Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
76 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
77 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
78 Product Information. Edecrin (ethacrynic acid). Merck &amp Co, Inc, West Point, PA.
79 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
80 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]